ANXA2 and neoplasm: The silencing of ANXA2 has also been found to increase the drug sensitivity of GC cells to DDP by the decrease in phosphorylation of P38MAPK and AKT, the downregulation of P-gp, MRP1, and Bcl-2, as well as the upregulation of Bax in tumor cells [69].